Personalized dosing for kidney cancer: a step toward better tolerability?
NCT ID NCT02555748
First seen Apr 04, 2026 · Last updated Jun 13, 2026 · Updated 9 times
Summary
This study looked at whether adjusting the dose of two common kidney cancer drugs (sunitinib and pazopanib) based on their levels in the blood can improve treatment outcomes. It involved 47 patients with advanced or metastatic kidney cancer. The goal was to see if this personalized approach reduces side effects and delays disease progression compared to the standard method of dosing based only on how patients feel.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH RODEZ
Rodez, 12027, France
-
CHU DE BORDEAUX - Hôpital Saint-André
Bordeaux, 33035, France
-
CHU DE LIMOGES - Hôpital Dupuytren
Limoges, 87042, France
-
Centre Leon Berard
Lyon, 69373, France
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut Claudius Regaud
Toulouse, 31059, France
-
Institut Paoli Calmettes
Marseille, 13273, France
-
Institut Regional Du Cancer Montpellier
Montpellier, 34298, France
Conditions
Explore the condition pages connected to this study.